HomeCompareCMVLF vs PM

CMVLF vs PM: Dividend Comparison 2026

CMVLF yields 64.94% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMVLF wins by $777.8K in total portfolio value
10 years
CMVLF
CMVLF
● Live price
64.94%
Share price
$3.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$827.5K
Annual income
$205,354.23
Full CMVLF calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — CMVLF vs PM

📍 CMVLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMVLFPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMVLF + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMVLF pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMVLF
Annual income on $10K today (after 15% tax)
$5,519.48/yr
After 10yr DRIP, annual income (after tax)
$174,551.10/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, CMVLF beats the other by $172,423.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMVLF + PM for your $10,000?

CMVLF: 50%PM: 50%
100% PM50/50100% CMVLF
Portfolio after 10yr
$438.6K
Annual income
$103,928.43/yr
Blended yield
23.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

CMVLF
Analyst Ratings
7
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
-0.9
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMVLF buys
0
PM buys
0
No recent congressional trades found for CMVLF or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMVLFPM
Forward yield64.94%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$827.5K$49.6K
Annual income after 10y$205,354.23$2,502.61
Total dividends collected$696.1K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CMVLF vs PM ($10,000, DRIP)

YearCMVLF PortfolioCMVLF Income/yrPM PortfolioPM Income/yrGap
1← crossover$17,194$6,493.51$11,650$409.56+$5.5KCMVLF
2$28,831$10,434.22$13,592$497.49+$15.2KCMVLF
3$47,202$16,352.17$15,882$605.21+$31.3KCMVLF
4$75,526$25,019.87$18,589$737.41+$56.9KCMVLF
5$118,227$37,414.37$21,794$899.94+$96.4KCMVLF
6$181,239$54,736.40$25,597$1,100.16+$155.6KCMVLF
7$272,346$78,420.28$30,118$1,347.30+$242.2KCMVLF
8$401,542$110,132.11$35,505$1,652.97+$366.0KCMVLF
9$581,404$151,754.11$41,940$2,031.88+$539.5KCMVLF
10$827,457$205,354.23$49,643$2,502.61+$777.8KCMVLF

CMVLF vs PM: Complete Analysis 2026

CMVLFStock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Full CMVLF Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this CMVLF vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMVLF vs SCHDCMVLF vs JEPICMVLF vs OCMVLF vs KOCMVLF vs MAINCMVLF vs MOCMVLF vs BTICMVLF vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.